Highest-materiality recent filing
Bluejay Diagnostics completes 624 of 750 patient enrollments in SYMON-II sepsis trial
SYMON-II pivotal trial for Symphony IL-6 sepsis triage test enrolled 624 of 750 target patients.
Bluejay Diagnostics reports FY2025 net loss $6.8M; cash $5.2M; needs >$20M additional capital
Net loss of ~$6.8M for FY2025; cash and cash equivalents $5.2M; stockholders' equity $6.0M as of Dec 31, 2025.
Bluejay Diagnostics enrolls 545 patients in SYMON™ II study, exceeds expectations
Enrolled 545 of 750 target patients in SYMON™ II multicenter IL-6 monitoring study, exceeding initial expectations.
Bluejay Diagnostics Q3 update: SYMON-II 50% enrolled, $3.08M cash, needs $20M more by 2027
Q3 cash $3.08M; stockholders' equity $3.69M. Raised $3.85M in April and $4.5M PIPE in October.
Bluejay Diagnostics raises $4.5M in private placement of stock and warrants
Gross proceeds of $4.5M; net proceeds ~$4.0M after 8% placement agent fee and expenses.
Bluejay expands SanyoSeiko partnership for Symphony platform commercialization
SanyoSeiko will serve as contract manufacturing organization for analyzers, cartridges, and components.
Bluejay Diagnostics Q2 update: SYMON-II enrollment starts, 510(k) target 2027
SYMON-II pivotal trial enrollment began; aims to validate IL-6 for 28-day mortality in ICU patients.
Bluejay Diagnostics mid-year update: cash $5.7M, headcount cut to 5, seeks $30M+ funding
SYMON-II pivotal sepsis trial enrolling; 510(k) submission planned for Q4 2027, FDA approval target Q3 2028.
CTO Jason Cook's employment ends May 30, 2025 under separation agreement.
Under the terms of the Separation Agreement, Dr. Cook will cease employment with the Company on May 30, 2025.
Max materiality 0.75 · Median 0.55 · Most common event other_material